SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
ELOX reported Third Quarter 2026 results. The price and volatility reaction is pending.
ELOXearnings

Earnings reactions, page 2

Eloxx Pharmaceuticals, Inc. (ELOX) Q3 FY2026 earnings

November 16, 2026 · SharpeIQ Research Desk

Reported results

  • Net loss for the three months ended September 30, 2026, was $5.5 million, or $(0.49) per basic and diluted share, compared to a net loss of $0.4 million, or $(0.58) per share, for the same period in 2025.
  • Research and development expenses were $4.0 million for the three months ended September 30, 2026, compared to a net credit of $0.3 million for the same period in 2025.
  • General and administrative expenses were $1.9 million for the three months ended September 30, 2026, compared to $0.5 million for the same period in 2025.
  • Other income, net was $0.4 million for the three months ended September 30, 2026, compared to other expense, net of $0.1 million for the same period in 2025.
  • Cash and cash equivalents were $56.3 million as of September 30, 2026, compared to $62.0 million as of June 30, 2026.

Guidance

  • The Company believes its cash and cash equivalents will be sufficient to fund its operations into 2028.

Notes

In May 2026, the Company effected a one-for-eleven reverse stock split of its common stock and reduced its authorized shares of common stock from 500,000,000 to 100,000,000; all share and per-share amounts in the press release reflect the reverse stock split.

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-16 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →